Pacgen Biopharmaceuticals - Product Pipeline: G31P

By: Pacgen Biopharmaceuticals  09-12-2011
Keywords: Clinical Development, Preclinical Studies, Inflammatory Disease

PAC-G31P

Pacgen is conducting a number of preclinical studies with PAC-G31P, a novel recombinant protein, to evaluate its potential in the prevention and the treatment for a number of acute and chronic inflammatory diseases characterized by non-beneficial neutrophil recruitment.

THE DRUG CANDIDATE

PAC-G31P is a novel peptide that is a synthetic derivative of the human cytokine, Interleukin-8 (IL-8). IL-8 is one of several alarm signal cytokines that stimulate neutrophil recruitment from circulation to the site of infection or injury. Based on the biological mechanism of action of PAC-G31P, ARDS has been identified as a possible lead clinical indication. Other inflammatory lung diseases such as pneumonia, asthma and chronic obstructive pulmonary disease may also be therapeutic targets for PAC-G31P.

MECHANISM OF ACTION

PAC-G31P acts by binding to two specific cell surface receptors, CXCR-1 and CXCR-2, found on neutrophils, that detect alarm signal cytokines. When PAC-G31P binds to the receptors, it blocks (or modulates) the actions of the cytokines responsible for neutrophil recruitment. In conditions such as ARDS where over-recruitment of neutrophils is part of the disease process, PAC-G31P is expected to block the receptors, overcome the excessive alarm signal, and restore a level of neutrophil recruitment that is appropriate to respond to the lung injury or infection.

DEVELOPMENT PLANS

The development program for PAC-G31P will be very complex and will address multiple acute and chronic market opportunities. For that reason, Pacgen expects to seek to partner this program at an earlier stage of development than its other programs.

PARTNERING PLANS

The development program for PAC-G31P will be very complex and will address multiple acute and chronic market opportunities. For that reason, Pacgen expects to seek to partner this program at an earlier stage of development than its other programs. PAC-G31P will also require extensive early commercial planning to optimize the value of the program. The treatment/prevention of ARDS, among other inflammatory diseases, is estimated to be a $3 billion market opportunity. Pacgen plans to partner the compound at a late preclinical or early clinical development stage.

PRECLINICAL RESULTS

Preclinical results to date suggest PAC-G31P has potential to reduce neutrophil recruitment to the injured lung. In preclinical models of inflammatory disease a bacterial lipposaccharide (LPS) is used to cause significant peripheral blood, pulmonary and airway neutrophilia which is similar to that observed in acute lung injury in humans. Treatment with PAC-G31P significantly reduced neutrophil infiltration into lung airways and tissues.

The information in this article was current at 06 Dec 2011

Keywords: Clinical Development, Inflammatory Disease, Neutrophil Recruitment, Preclinical Studies,

Contact Pacgen Biopharmaceuticals

Email

Print this page

Other products and services from Pacgen Biopharmaceuticals

09-12-2011

Pacgen Biopharmaceuticals - Product Pipeline: Pipeline

The Phase IIb study, which involved over 200 seropositive HIV patients, demonstrated that PAC-113 efficacy profile compares favorably to the efficacy of Nystatin, a current standard of care for topical treatment of oral Candidiasis. The most advanced of three candidates is a peptide therapeutic, PAC-G31P, which is currently being investigated in preclinical studies for its potential to treat inflammatory disease.


09-12-2011

Pacgen Biopharmaceuticals - Product Pipeline: PAC 113

The growth of this market and demand for effective anti-fungals is driven by a rising incidence of immunocompromised patients populations including individuals with HIV, cancer, asthma and diabetes, among others. Candida albicans is the most common fungal pathogen among immune-compromised, hospitalized patients, accounting for roughly 50-60% of all bloodstream fungal isolates.


09-12-2011

Pacgen Biopharmaceuticals - Publications & Presentations

Eva J. Helmerhorst, Frank G Oppenheim, Lewis Choi, David Cheng, Neil E. Reiner ‚“Evaluation of a New Host-Derived Synthetic antifungal Peptide in the Treatment of Oral Candidiasis“presented at the 5th International Meeting on Antimicrobial Chemotherapy in Clinical Practice, November 25-17, 2007.